戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sodilating beta-blockers (eg, carvedilol and nebivolol).
2 tolic blood pressure from baseline than both nebivolol 40 mg/day (least-squares mean difference -1.2
3 ay, 5 and 160 mg/day, or 10 and 160 mg/day), nebivolol (5 mg/day or 20 mg/day), valsartan (80 mg/day
4                                              Nebivolol (500 ng/kg) reduced INF/AAR by 37% (p < 0.001
5                                              Nebivolol (500 ng/kg), CL 316243 (1 mug/kg), BRL-37344 (
6 his study sought to test the hypothesis that nebivolol, a beta1-antagonist and beta2,3-agonist, may i
7 helial dysfunction in blacks was tested with nebivolol, a beta1-selective agent with vasodilating and
8                         We hypothesized that nebivolol, a vasodilating beta-blocker, could improve en
9  this hypothesis by comparing the effects of nebivolol and atenolol on endothelial function.
10                                              Nebivolol and carvedilol are third-generation beta-adren
11  results demonstrate for the first time that nebivolol and carvedilol induce relaxation of renal glom
12                         We hypothesized that nebivolol and carvedilol stimulate NO release from micro
13                The maximum of NO release for nebivolol and carvedilol was very similar (188+/-14 and
14                                              Nebivolol and CL 316243 increased eNOS phosphorylation a
15                                              Nebivolol and CL 316243 significantly increased myocardi
16 15 to 4 weeks of double-blind treatment with nebivolol and valsartan fixed-dose combination (5 and 80
17                                              Nebivolol and valsartan fixed-dose combination is an eff
18  combination of a vasodilating beta blocker (nebivolol) and an angiotensin II receptor blocker (valsa
19  of the potent antihypertensive beta-blocker nebivolol are reported.
20 etylcholine was significantly increased with nebivolol/bendrofluazide (maximum percentage change in f
21                                              Nebivolol/bendrofluazide and atenolol/bendrofluazide eac
22                                              Nebivolol/bendrofluazide increased both stimulated and b
23  a growth abnormality that was normalized by nebivolol but not by metoprolol.
24 This pathological phenotype was corrected by nebivolol but not metoprolol in a dose-dependent fashion
25                                              Nebivolol but not metoprolol induced endothelium-depende
26                                              Nebivolol could be a promising option for the management
27                                              Nebivolol decreased O2- and ONOO- concentrations and res
28                                              Nebivolol failed to reduce INF after MI/R in beta(3)-AR
29 re, vasodilating beta-blockers, particularly nebivolol, have positive effects on endothelial function
30                                        Thus, nebivolol may offer additional vascular protection in tr
31                               The effects of nebivolol on endothelial nitric oxide (NO), superoxide (
32                  This paper examined whether nebivolol protects the heart via nitric oxide (NO) synth
33      Pretreatment with 1.0 to 5.0 micromol/L nebivolol restored NO bioavailability in endothelial cel
34  L-NMMA was significantly improved only with nebivolol treatment (percentage change in forearm blood
35                                              Nebivolol was more potent than metoprolol in improving c
36                               The effects of nebivolol were dose-dependent and not observed with aten
37 8-week treatment periods with either 5 mg of nebivolol with 2.5 mg of bendrofluazide or 50 mg of aten
38                   We compared the effects of nebivolol with metoprolol, a first-generation beta1-sele

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。